VERTEX PHARMACEUTICALS INC / MA (VRTX) Net margin 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) net profit margin by fiscal year — reported net income divided by reported revenue.
32.9%FY2025 · since FY2016: -6.6% → 32.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 32.9% | +37.8 pp |
| FY2024 | -4.9% | -41.5 pp |
| FY2023 | 36.7% | -0.5 pp |
| FY2022 | 37.2% | +6.3 pp |
| FY2021 | 30.9% | -12.8 pp |
| FY2020 | 43.7% | +15.4 pp |
| FY2019 | 28.3% | -40.5 pp |
| FY2018 | 68.8% | +58.2 pp |
| FY2017 | 10.6% | +17.2 pp |
| FY2016 | -6.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Gross profitVRTX Gross marginVRTX Operating incomeVRTX Operating marginVRTX Operating cash flowVRTX Free cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →